RPRohini Palekar

Rohini Palekar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rohini Palekar has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sustainable and stability-indicating RP-HPLC method for Tofacitinib: an integrated white analytical chemistry and A-QbD approach

    by Suchita Waghmare, Ujban Hussain, Rohini Palekar, Pratiksha Bramhe, Nilesh Rarokar, Pramod Khedekar


  • Open Access

    QbD-optimized HA–Pluronic nanomicelles for the targeted repurposing of tofacitinib in breast cancer

    by Suchita Waghmare, Rohini Palekar, Pratiksha Bramhe, Nilesh Rarokar, Pramod Khedekar

    Tofacitinib, a Janus kinase (JAK) inhibitor clinically approved for rheumatoid arthritis, holds significant potential for repurposing in breast cancer therapy due to its ability to suppress the oncogenic STAT3 signaling pathway; however, its therapeutic application is hindered by poor aqueous solubility, rapid systemic clearance, and non-specific distribution. To address these limitations, this study aimed to develop hyaluronic acid (HA)-decorated Pluronic F127 (PF127) micelles to enhance the solubility, bioavailability, and targeted delivery of Tofacitinib to CD44-overexpressing breast cancer cells. A Quality by Design (QbD) approach utilizing a Box–Behnken design (BBD) was employed to systematically optimize critical process parameters—drug-to-polymer ratio, polymer concentration, and stirring temperature—to minimize particle size and polydispersity index (PDI) while maximizing entrapment efficiency. The optimized micelles exhibited a uniform particle size of 159.2 ± 3.8 nm, a narrow PDI of 0.221, a high entrapment efficiency of 91.14%, and a negative zeta potential of −24.6 mV, ensuring colloidal stability. In vitro evaluation demonstrated a sustained, diffusion-controlled drug release profile and significantly enhanced cytotoxicity against MCF-7 breast cancer cells (IC50 14.2 µg mL−1) compared to the free drug (IC50 46.8 µg mL−1), attributed to CD44-mediated cellular uptake. Furthermore, in vivo pharmacokinetic analysis in Wistar rats revealed a 4.3-fold increase in oral bioavailability and a prolonged elimination half-life compared to free Tofacitinib, while histopathological studies confirmed the formulation's biocompatibility and safety in major organs. These findings collectively support the viability of the QbD-optimized HA–PF127 micellar system as a promising nanocarrier platform for the effective oral repurposing of Tofacitinib in breast cancer treatment.


  • VEGF/VEGFR: A Novel Therapy Target in Cancer

    by Deepali Wanode, Deweshri Nandurkar, Rohini Palekar, Kumud Bhendarkar, Pramod Khedekar

    Angiogenesis reduction with VEGF/VEGFR (Vascular Endothelial Growth Factor/ Vascular Endothelial Growth Factor Receptor) inhibition is the target of our review. Angiogenesis is the development of blood vessels and affects cancer spread and progression. The angiogenesis process is triggered by a number of growth factors, including cytokines, VEGF, FGF (fibroblast growth factor), and PDGF (platelet-derived growth factor). VEGF and VEGFR are two factors that significantly impact the angiogenesis process. VEGFRs are Kinase Domain Receptors (KDRs). Upon activation, KDRs trigger autophosphorylation, which leads to tumor growth, metastasis, and cell proliferation. Numerous cancer types, including breast, renal, non-small cell lung, cervical, hepatocellular, and others, have been linked to overexpression of VEGFR. It has been established that VEGF/ VEGFR overexpression or gene amplification occurs in certain malignancies. Furthermore, an increasing amount of research has shown that blocking VEGF/VEGFR may enhance the effects of chemotherapy. In recent decades, several VEGF/VEGFR inhibitors have been developed that effectively inhibit the growth and progression of several malignancies in vivo and in vitro, suggesting that VEGF/VEGFR could be a novel target for therapeutic intervention. In this review, we started by quickly going over the composition, location, and physiological roles of VEGF/VEGFR during mitosis. The oncogenic function of VEGF/VEGFR in the development of cancer has then been covered. Lastly, we have discussed the prospective anticancer therapy provided by the clinically authorized VEGFR inhibitors.